Haplotype-based Association of Vascular Endothelial Growth Factor Gene Polymorphisms with Urothelial Bladder Cancer Risk in Tunisian Population

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2018 Jul 1

PMID 29959793

Citations 6

Authors

Safa Ben Wafi

Amani Kallel

Mohamed Kacem Ben Fradj

Ahmed Sallemi

Sami Ben Rhouma

Meriam Ben Halima

Haifa Sanhaji

Yassine Nouira

Riadh Jemaa

Moncef Feki

Affiliations

Soon will be listed here.

Abstract

Background/aim: Accumulated data suggested that Vascular Endothelial Growth Factor is a major mediator in vasculogenesis, angiogenesis and recently in tumorigenesis. Therefore, we aimed to investigate for the first time the association between VEGF gene variants (-2549I/D (rs35569394), -2578C/A (rs699947), and +936C/T (rs3025039)) with urothelial bladder cancer (UBC) in Tunisian population.

Methods: A total of 218 UBC patients and 204 controls were recruited and genotyped by Polymerase Chain Reaction technique. Odds ratios (OR) and 95% confidence intervals (CIs) were used to access the association between the VEGFA gene polymorphisms and UBC.

Results: We found a significant decreased risk association of -2578 C/A polymorphism with UBC (OR (95% CI), 0.62 (0.41-0.94), P = .026) for CA genotype and (OR (95% CI), 0.40 (0.21-0.76), P = .005) for double homozygous mutant genotype. No associations were found in case of both polymorphic sites of VEGF, vis. -2549I/D and +936C/T, respectively. Haplotype analysis revealed a strong linkage disequilibrium between -2578C/A and -2549I/D and CIC combination is the significant haplotype associated with increased risk of UBC (OR (95% CI), 3.63 (1.47-8.97), P = .005). Regarding tumor grade/stage and family history of cancer, no associations were found for -2578C/A polymorphism.

Conclusion: CIC haplotype of VEGF gene may be important risk factor for UBC development in Tunisia.

Citing Articles

Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features.

Abbas N, Aoude M, Kourie H, Al-Shamsi H Asian J Urol. 2024; 11(3):406-422.

PMID: 39139531 PMC: 11318450. DOI: 10.1016/j.ajur.2023.10.001.

Genetic Polymorphisms Involved in Bladder Cancer: A Global Review.

Kourie H, Zouein J, Succar B, Mardirossian A, Ahmadieh N, Chouery E Oncol Rev. 2023; 17:10603.

PMID: 38025894 PMC: 10657888. DOI: 10.3389/or.2023.10603.

The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer.

El Azzouzi M, El Ahanidi H, Hafidi Alaoui C, Chaoui I, Benbacer L, Tetou M Diagnostics (Basel). 2023; 13(8).

PMID: 37189572 PMC: 10137622. DOI: 10.3390/diagnostics13081471.

Association of VEGF haplotypes with breast cancer risk in North-West Indians.

Sambyal V, Guleria K, Kapahi R, Manjari M, Sudan M, Uppal M BMC Med Genomics. 2021; 14(1):209.

PMID: 34429108 PMC: 8386001. DOI: 10.1186/s12920-021-01060-4.

Effect of vascular endothelial growth factor rs35569394 in esophageal cancer and response to chemotherapy.

Wang Z, Li C, Li X, Shi J, Wu W Biomol Biomed. 2021; 23(2):271-276.

PMID: 34157252 PMC: 10113952. DOI: 10.17305/bjbms.2021.5891.

References

Luo T, Chen L, He P, Hu Q, Zhong X, Sun Y . Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population. Asian Pac J Cancer Prev. 2013; 14(4):2433-7. DOI: 10.7314/apjcp.2013.14.4.2433. View

Hsiao P, Lu M, Chiang F, Shin S, Tai Y, Juo S . Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol. 2007; 195(2):265-70. DOI: 10.1677/JOE-07-0395. View

Kapahi R, Guleria K, Sambyal V, Manjari M, Sudan M, Uppal M . Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians. Tumour Biol. 2015; 36(6):4223-34. DOI: 10.1007/s13277-015-3059-1. View

Naikoo N, Afroze D, Rasool R, Shah S, Ahangar A, Bhat I . SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir. Asian Pac J Cancer Prev. 2017; 18(7):1799-1804. PMC: 5648382. DOI: 10.22034/APJCP.2017.18.7.1799. View

Yang Y, Zhang X, Song D, Wei J . Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk. Mol Clin Oncol. 2014; 2(4):501-505. PMC: 4051574. DOI: 10.3892/mco.2014.296. View

Jaiswal P, Tripathi N, Shukla A, Mittal R . Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk. Med Oncol. 2013; 30(2):509. DOI: 10.1007/s12032-013-0509-8. View

Kamoun M, Houman M, Hamzaoui A, Hamzaoui K . Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet's disease. Tissue Antigens. 2008; 72(6):581-7. DOI: 10.1111/j.1399-0039.2008.01145.x. View

Zidi S, Stayoussef M, Gazouani E, Mezlini A, Yacoubi-Loueslati B, Almawi W . Relationship of common vascular endothelial growth factor polymorphisms and haplotypes with the risk of cervical cancer in Tunisians. Cytokine. 2014; 74(1):108-12. DOI: 10.1016/j.cyto.2014.11.009. View

Prakash S, Prasad N, Sharma R, Faridi R, Agrawal S . Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine. 2012; 58(2):261-6. DOI: 10.1016/j.cyto.2012.01.020. View

10.

Shibuya M . Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008; 41(4):278-86. DOI: 10.5483/bmbrep.2008.41.4.278. View

11.

Carmeliet P . Angiogenesis in health and disease. Nat Med. 2003; 9(6):653-60. DOI: 10.1038/nm0603-653. View

12.

Jacobs E, Feigelson H, Bain E, Brady K, Rodriguez C, Stevens V . Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22. PMC: 1557725. DOI: 10.1186/bcr1400. View

13.

Ke Q, Liang J, Wang L, Hu Z, Jin G, Zhou Y . Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog. 2008; 47(8):647-51. DOI: 10.1002/mc.20435. View

14.

Saenz-Lopez P, Vazquez F, Cozar J, Carretero R, Garrido F, Ruiz-Cabello F . VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol. 2012; 74(1):98-103. DOI: 10.1016/j.humimm.2012.10.014. View

15.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher T . A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003; 106(4):468-471. DOI: 10.1002/ijc.11238. View

16.

Rezaei M, Hashemi M, Sanaei S, Mashhadi M, Taheri M . Association Between Vascular Endothelial Growth Factor Gene Polymorphisms with Breast Cancer Risk in an Iranian Population. Breast Cancer (Auckl). 2016; 10:85-91. PMC: 4933538. DOI: 10.4137/BCBCR.S39649. View

17.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P . The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012; 133(2):769-78. DOI: 10.1007/s10549-012-1980-1. View

18.

Ben Wafi S, Kallel A, Fradj M, Sallemi A, Ben Rhouma S, Ben Halima M . Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population. J Clin Lab Anal. 2018; 32(9):e22610. PMC: 6817149. DOI: 10.1002/jcla.22610. View

19.

Garcia-Closas M, Malats N, Real F, Yeager M, Welch R, Silverman D . Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet. 2007; 3(2):e29. PMC: 1802828. DOI: 10.1371/journal.pgen.0030029. View

20.

Liu F, Luo L, Wei Y, Wang W, Wen T, Yang J . Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population. Oncotarget. 2017; 8(10):16488-16497. PMC: 5369979. DOI: 10.18632/oncotarget.14870. View